Pharmaceuticals News and Research

RSS

Lab study shows effectiveness of potential therapy for treatment-resistant hypothyroidism

A new "metal-coordinated" drug-delivery technology potentially could be used to supplement the standard therapy for hypothyroidism, which affects nearly 10 million Americans, and many more patients worldwide, according to results of a study published in the journal Thyroid this month.

15 Oct 2018

Unapproved pharmaceutical ingredients identified in many over-the-counter dietary supplements

Potentially harmful and undeclared pharmaceuticals were identified in more than 700 over-the-counter dietary supplements in an analysis of U.S. Food and Drug Administration warnings from 2007 through 2016.

12 Oct 2018

Podcast: KHN’s ‘What the Health?’ Falling premiums and rising political tensions

The Trump administration announced that, for the first time, the average premium for a key plan sold on the federal health law's insurance marketplaces will fall slightly next year. Federal officials said that changes they have made helped facilitate the reduction, but others argue that it was because more plans are moving back into those federal exchanges and making money.

11 Oct 2018

Ritual for orthodox Jewish men may offer cardiovascular health benefits, study suggests

A pilot study led by researchers at the University of Cincinnati College of Medicine suggests Jewish men who practice wearing tefillin, which involves the tight wrapping of an arm with leather banding as part of daily prayer, may receive cardiovascular health benefits.

11 Oct 2018

Flavoring, additive ingredients in e-cigarettes may increase inflammation and impair lung function

Flavoring and additive ingredients in e-cigarettes may increase inflammation and impair lung function, according to new research.

11 Oct 2018

Carnegie scientist awarded NIH grant to identify novel medicines for cardiovascular disease

Carnegie's Department of Embryology scientist Steven Farber and team have been awarded a 5-year $3.3-million NIH grant to identify novel pharmaceuticals for combatting a host of diseases associated with altered levels of lipoproteins like LDL ("bad cholesterol").

11 Oct 2018

Federal grant awarded to Indiana University researcher-entrepreneur for startup

A high-tech startup founded by an Indiana University researcher-entrepreneur has been awarded a federal grant to develop technology that aims to reduce the use of animals in chemical toxicity studies of food, pharmaceuticals, pesticides and other products.

10 Oct 2018

Scientists identify new biomarker for Alzheimer's disease of sporadic origin

The objective of the research, undertaken in the laboratories of the IBPM, is to develop a model for studying Alzheimer's disease of sporadic origin, in other words, not due to a hereditary genetic mutation.

10 Oct 2018

New pre-clinical research shows utility of mRNA platform to treat rare metabolic disorders

An mRNA platform that can express therapeutic levels of protein in liver tissue could be used to treat patients with rare metabolic disorders.

9 Oct 2018

Black market for suboxone gives some a glimpse of recovery

Months in prison didn’t rid Daryl of his addiction to opioids. “Before I left the parking lot of the prison, I was shooting up, getting high,” he said.

9 Oct 2018

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

Verastem, Inc., focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the National Comprehensive Cancer Network added COPIKTRA (duvelisib) capsules to the Clinical Practice Guidelines in Oncology (NCCN Guidelines) for follicular lymphoma.

8 Oct 2018

FDA and EMA accept Novartis' regulatory application for siponimod to treat SPMS in adults

Novartis today announced that both the US Food and Drug Administration and European Medicines Agency have accepted the company's New Drug Application and Marketing Authorization Application respectively, for investigational oral, once-daily siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis in adults.

8 Oct 2018

New method for quantification of liposome formulated drugs

Postnova Analytics has published an application study that describes a new method for quantification of liposome encapsulated drug using Centrifugal Field-Flow Fractionation

From Postnova Analytics 5 Oct 2018

FDA approves HEMLIBRA for treatment of hemophilia A

Chugai Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved HEMLIBRA (US generic name: emicizumab-kxwh), a treatment for hemophilia A created by Chugai, for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A without factor VIII inhibitors, administered once weekly, every two weeks, or every four weeks.

5 Oct 2018

Congress targets misuse of hospice drugs

Hospice workers would be allowed to destroy patients’ unneeded opioids, reducing the risk that families misuse them, according to one little-noticed provision in the bipartisan opioids bill headed to President Donald Trump’s desk for his likely signature.

5 Oct 2018

Clemson University researcher reveals insights into rapid spread of homemade steroids

A Clemson University researcher recently published insights into homemade steroids and steroid trafficking through a study of federal court cases. The research details why homemade steroids became popular and how online tools and cryptocurrency have allowed for their rapid spread.

4 Oct 2018

Podcast: KHN’s ‘What the Health?’ Some things old, some things new

Congress passed major health-related legislation in time for the fiscal year, which began Monday, including a broad bill to address the opioid epidemic and a spending bill for the Department of Health and Human Services.

4 Oct 2018

Alnylam announces positive results from Phase 1/2 study of lumasiran for treating primary hyperoxaluria-1

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today updated positive results from its Phase 1/2 clinical study of lumasiran, an investigational, subcutaneously administered RNAi therapeutic targeting glycolate oxidase for the treatment of primary hyperoxaluria type 1.

4 Oct 2018

MD Anderson and Cyclacel announce strategic alliance to evaluate novel drugs for hematological malignancies

The University of Texas MD Anderson Cancer Center and Cyclacel Pharmaceuticals, Inc., today announced a three-year strategic alliance agreement that will enable clinical evaluation for safety and efficacy of three Cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and other advanced leukemias.

4 Oct 2018

Alnylam submits CTA application to MHRA to initiate Phase 1/2 study of ALN-AAT02

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that it has submitted a Clinical Trial Authorization application to the Medicines and Healthcare products Regulatory Agency to initiate a Phase 1/2 study of ALN-AAT02, an investigational RNAi therapeutic targeting alpha-1 antitrypsin for the treatment of AAT deficiency-associated liver disease.

3 Oct 2018

Pharmaceuticals News and Research

Lab study shows effectiveness of potential therapy for treatment-resistant hypothyroidism

Unapproved pharmaceutical ingredients identified in many over-the-counter dietary supplements

Podcast: KHN’s ‘What the Health?’ Falling premiums and rising political tensions

Ritual for orthodox Jewish men may offer cardiovascular health benefits, study suggests

Flavoring, additive ingredients in e-cigarettes may increase inflammation and impair lung function

Carnegie scientist awarded NIH grant to identify novel medicines for cardiovascular disease

Federal grant awarded to Indiana University researcher-entrepreneur for startup

Scientists identify new biomarker for Alzheimer's disease of sporadic origin

New pre-clinical research shows utility of mRNA platform to treat rare metabolic disorders

Black market for suboxone gives some a glimpse of recovery

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

FDA and EMA accept Novartis' regulatory application for siponimod to treat SPMS in adults

New method for quantification of liposome formulated drugs

FDA approves HEMLIBRA for treatment of hemophilia A

Congress targets misuse of hospice drugs

Clemson University researcher reveals insights into rapid spread of homemade steroids

Podcast: KHN’s ‘What the Health?’ Some things old, some things new

Alnylam announces positive results from Phase 1/2 study of lumasiran for treating primary hyperoxaluria-1

MD Anderson and Cyclacel announce strategic alliance to evaluate novel drugs for hematological malignancies

Alnylam submits CTA application to MHRA to initiate Phase 1/2 study of ALN-AAT02

Pittcon Highlights: Pharmaceutical & Biologic eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring